AstraZeneca starts new study of heart drug Brilinta
LONDON, July 17
LONDON, July 17 (Reuters) - AstraZeneca is to conduct a new global clinical trial of its heart drug Brilinta involving 11,500 patients with peripheral artery disease, Britain's second biggest drugmaker said on Tuesday.
Peripheral artery disease affects around 27 million people in Europe and North America. Sufferers are at high risk of heart attacks, strokes and other complications.
The new study will compare AstraZeneca's medicine, which is currently only approved for patients with acute coronary syndromes, against its older rival Plavix.
- China food scandal spreads, drags in Starbucks, Burger King and McNuggets in Japan |
- Israel pounds Gaza despite international peace efforts |
- Train carrying MH17 bodies on final journey reaches Ukraine city |
- Islamic State crushes and coerces on march towards Baghdad
- EU threatens Russia with more sanctions, but words ring hollow